ProKidney (PROK) vs Sagimet Biosciences Series A (SGMT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Sagimet Biosciences Series A (SGMT) has outperformed ProKidney (PROK) over the past year, gaining 21.0% versus a loss of 47.0%. ProKidney is the larger company by market cap ($640.9 million vs $623.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PROK | SGMT |
|---|---|---|
| Share price | $1.61 | $8.79 |
| Market cap | $640.89M | $623.29M |
| 1-day change | +2.26% | -1.01% |
| YTD return | -29.91% | +50.00% |
| 1-year return | -46.96% | +20.98% |
| 5-year return | -84.09% | — |
| EPS (TTM) | $-0.55 | $-1.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.48 | $11.45 |
| 52-week low | $1.30 | $4.50 |
| Distance from 52-week high | -53.86% | -23.22% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +289.29% | +217.52% |
| Average volume | 1.30M | 1.23M |
| Shares outstanding | 208.93M | 70.34M |
| Employees | 231 | 16 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SGMT has outperformed PROK by 67.9 percentage points over the past year.
About ProKidney
PROK stock →ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 231 employees
About Sagimet Biosciences Series A
SGMT stock →Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
PROK vs SGMT FAQ
Which is bigger, ProKidney or Sagimet Biosciences Series A?
ProKidney (PROK) is larger, with a market capitalization of $640.89M compared with $623.29M for Sagimet Biosciences Series A (SGMT).
Which stock has performed better over the past year, PROK or SGMT?
SGMT returned +20.98% over the past 12 months, compared with -46.96% for PROK (price return, excluding dividends). Past performance does not predict future results.
Are ProKidney and Sagimet Biosciences Series A in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for ProKidney and Biotechnology: Pharmaceutical Preparations for Sagimet Biosciences Series A.